Sector: Healthcare | Industry: Healthcare Facilities & Services |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 2000 16th St DENVER CO 80202-5158 |
Tel: | 1-303-8766621 |
Website: | https://www.davita.com |
IR: | See website |
Key People | ||
Javier J. Rodriguez Chief Executive Officer, Director | Joel Ackerman Chief Financial Officer, Treasurer | Christopher Michael Berry Chief Accounting Officer |
James O. Hearty Chief Compliance Officer | Michael D. Staffieri Chief Operating Officer - DaVita Kidney Care | Kathleen Alyce Waters Chief Legal and Public Affairs Officer |
Business Overview |
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis and related lab services (U.S. dialysis) business treats patients with chronic kidney failure, end-stage kidney disease (ESKD). The Company's robust platform delivers kidney care services and also includes established nephrology and payor relationships. The Company's international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company's U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations. |
Financial Overview |
For the fiscal year ended 31 December 2023, Davita Inc revenues increased 5% to $12.14B. Net income before extraordinary items increased 26% to $691.5M. Revenues reflect U.S. dialysis segment increase of 3% to $10.85B, Other'��Ancillary services segment increase of 18% to $1.29B. Net income benefited from U.S. dialysis segment income increase of 13% to $1.77B, Other'��Ancillary services segment loss decrease of 91% to $8.7M. |
Employees: | 70,000 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $19,060M as of Dec 31, 2023 |
Annual revenue (TTM): | $12,140M as of Dec 31, 2023 |
EBITDA (TTM): | $2,513M as of Dec 31, 2023 |
Net annual income (TTM): | $691.54M as of Dec 31, 2023 |
Free cash flow (TTM): | $1,491M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $8,000M as of Dec 31, 2023 |
Shares outstanding: | 87,700,000 as of Jan 31, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |